Angelini Pharma has entered a definitive agreement to acquire Catalyst Pharmaceuticals (NasdaqCM:CPRX). The deal marks Angelini Pharma's planned entry into the U.S. market focused on brain health and ...

Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...

Under the definitive agreement, Italian pharmaceutical group will buy all outstanding shares of Catalyst Pharmaceuticals for $31.50 per share in cash.

The acquisition involves Angelini Pharma purchasing all outstanding Catalyst shares for $31.50 per share in cash.

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, ...

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035Catalyst has No Other FIRDAPSE ...

Angelini Pharma said on Thursday that it would ‌acquire U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker's entry into the U.S. pharmaceutical ...

Catalyst Pharmaceuticals, Inc. has announced that it will release its financial results for the first quarter of 2025 on May 7, 2025, after the market closes. Following this, the company's management ...

Catalyst Pharmaceuticals reported 2024 revenues of $491.7 million, projecting growth to $545-$565 million in 2025. Catalyst Pharmaceuticals, Inc. reported a record total revenue of $491.7 million for ...

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% ...

Catalyst Pharmaceuticals' specialty is treating rare diseases, which inherently leaves it off of most investors' radars. Nevertheless, growth is relative, and this company's relative growth right now ...